Bristol-Myers lassos the next big thing in I/O, grabs '214 rights in a record $3.6B deal with Nektar
After figuring for days in a swirling mix of rumors about a possible buyout, Nektar Therapeutics $NKTR is putting an end to the buzz with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
